

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02853 A3

(51) International Patent Classification⁷: G01N 33/86

[BE/BE]; Ommegangstraat 3, B-8550 Zwevegem (BE).
DECKMYN, Hans [BE/BE]; Lemingstraat 1, B-3210
Linden (BE).

(21) International Application Number: PCT/EP00/06345

(74) Agent: VOSSIUS & PARTNER; Siebertstr. 4, D-81675
München (DE).

(22) International Filing Date: 5 July 2000 (05.07.2000)

(81) Designated States (national): JP, US.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(26) Publication Language: English

Published:

— With international search report.

(30) Priority Data:

99112967.7 5 July 1999 (05.07.1999) EP

(88) Date of publication of the international search report:
12 July 2001

(71) Applicant (for all designated States except US): ROCHE

DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse

116, D-68305 Mannheim (DE).


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAUWEN-

BERGHS, Nancy [BE/BE]; Benningsbrugstraat 56A,
B-9032 Gent (BE). VANHOORELBEKE, Karen

(54) Title: DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY



WO 01/02853 A3

(57) Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(α) (GPIb(α) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(α), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.